Navigation Links
SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
Date:5/24/2013

SAN DIEGO, May 24, 2013 /PRNewswire/ -- Senomyx, Inc. (NASDAQ: SNMX), a  company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients, announced today that David Linemeyer , Ph.D., the Company's Vice President, Biology and Gwen Rosenberg , Vice President, Investor Relations & Corporate Communications, will present an overview of Senomyx's technology and programs on Friday, May 31, at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during the Citi 2013 Global Consumer Conference.  The conference is taking place at the Hilton New York Hotel in New York, NY.  During the presentation, Dr. Linemeyer and Ms. Rosenberg will discuss corporate developments including the Company's pipeline of novel flavor ingredients and its business strategy.

To access the live presentation or a subsequent archived recording, please log onto Senomyx's website at http://www.senomyx.com and click on the "Investor Relations" tab.  The archived webcast will be available for 30 days following the presentation.  Please connect to Senomyx's website prior to the start of the webcast to ensure adequate time to download any software that may be necessary.

About Senomyx, Inc. (www.senomyx.com)
Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
2. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
4. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
5. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
7. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
8. [Webcast] RateMyProduct, Product Assessment Tool for Life Science Suppliers
9. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
10. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
11. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... California (PRWEB) April 23, 2015 ... diagnostics refer to a series of genetic tests ... cystic fibrosis, Lou Gehrig's disease, Huntington's disease, and ... examining the gene composition and interaction in diseased ... disease as well as the response to treatment, ...
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company focused ... Patent and Trademark Office has issued 2 new patents ... US Pat. No. 8,986,727 was issued on March 24, ... for the sustained release of therapeutic agents. The ... (zero-order) release of large and small molecules for several ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... , ANNAPOLIS, Md. , Feb. 1 ... biodefense company developing medical countermeasures against biological and chemical ... Paper in response to the Broad Agency Announcement (Solicitation ... Development Authority (BARDA) for the Advanced Research and ...
... , Feb. 1 Telik, Inc. (Nasdaq: TELK ) ... 12th Annual BIO CEO & Investor Conference in New York City ... time ( 12:00 p.m. Pacific time ).  A live and archived ... www.telik.com . , Telik, Inc. of Palo Alto, CA , is ...
... , SAN FRANCISCO , Feb. 1 ... a placement agent in GenVec, Inc.,s (Nasdaq: GNVC ) ... stock, and warrants to purchase 4.2 million shares of common stock, ... http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with the Merriman team ...
Cached Biology Technology:PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 2PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 3PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Cancer Research Center have, for the first time, induced ... achievement, the first demonstration of "hibernation on demand" in ... treat cancer and prevent injury and death from insufficient ... in essence, temporarily converting mice from warm-blooded to cold-blooded ...
... that are invisible by ordinary means of detection, according ... of Medicine in St. Louis. , The researchers demonstrated ... from the surrounding tissue by direct MRI scan--could be ... minutes after the mice were injected with the nanoparticles. ...
... the March issue of the journal Cancer Cell describes a ... to a new avenue for targeted cancer therapy. The compound, ... mouse model system and has low toxicity. The results of ... in phase I clinical trials. , Plk1 is a molecule ...
Cached Biology News:Buying Time Through Hibernation on Demand 2Buying Time Through Hibernation on Demand 3Buying Time Through Hibernation on Demand 4Buying Time Through Hibernation on Demand 5Nanoparticles offer new hope for detection and treatment 2Nanoparticles offer new hope for detection and treatment 3New drug shows promise as powerful anticancer agent 2